Evaluation of synthetic peptide EIA for HIV-1 and HIV-2 for use in seroprevalence studies.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Evaluation of synthetic peptide EIA for HIV-1 and HIV-2 for use in seroprevalence studies.

Abstr Annu Meet Am Soc Microbiol. 1991 May 5-9;91:336 (abstract no. T-14). Unique Identifier : AIDSLINE ASM91/0270292
George R; Granade T; Holloman D; Schochetman G; De Cock K; Gayle H; Phillips S; Centers for Disease Control, Atlanta, GA.

Abstract: Three commercial synthetic peptide EIAs (PEIA) for HIV-1 and -2 antibody and a combined HIV-1/2 EIA were evaluated for their sensitivity and specificity as compared to FDA-licensed whole virus lysate EIAs (VEIA) and Western blots (WB). A panel of 107 HIV-1 weakly reactive sera, 19 HIV-1 seroconversion panels, and 158 HIV-2 sera were tested. The PEIA-1 and -2 found to be most sensitive and specific were used in an screening algorithm to test 1019 IVDUs for HIV-1 and -2. Results were compared to a standard testing algorithms (VEIA followed by WB.) The sensitivity of the PEIAs for HIV-1 ranged from 89.1% to 99.2%. Genetic Systems PEIA-1 and -2 were the most sensitive and specific assays. A screening algorithm including PEIAs for HIV-1 and -2 identified all infected specimens, slightly reduced the number of WB indeterminate results, but was more expensive than VEIA + WB.

Keywords: Blotting, Western Enzyme-Linked Immunosorbent Assay/ECONOMICS Human HIV Antibodies/*ANALYSIS *HIV Seroprevalence HIV-1/*IMMUNOLOGY HIV-2/*IMMUNOLOGY *Peptides Sensitivity and Specificity ABSTRACT
920830
M9281056

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .